|
|
Regional,
Monthly All-Breed Horse Magazine
•
Since 1993 |
|||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
|
Pfizer Animal Health’s QUEST® PLUS Dewormer is BackLong-Lasting
Deworming Helps Protect Against Tapeworms
QUEST® PLUS (moxidectin/praziquantel), is a
long-lasting, effective dewormer that helps protect against a broad range
of parasites including large and small strongyles, roundworms, pinworms,
hairworms, stomach worms, bots, and encysted small strongyles (bloodworms).
QUEST PLUS contains the same active ingredients as QUEST® (moxidectin)
gel, but with the additional benefit of praziquantel for treatment and control
of tapeworms (A.perfoliatum). Both dewormers provide up to 84 days of
protection from strongyle egg reinfection and 14 days without inflammation in
just one dose[i].
“We are thrilled to have QUEST PLUS back on the shelves and available
for our customers,” said Kristin Ruff, Director at Pfizer Animal Health.
“Pfizer Animal Health offers the most comprehensive deworming product
portfolio. Now with QUEST PLUS back in the mix, the portfolio is truly
complete.”
Tapeworms can pose a medical threat to horses across the
Horse owners can ensure their horses are protected from tapeworms by
incorporating a praziquantel dewormer, such as QUEST PLUS, into their deworming
program. This class of anthelmintic has been proven effective against tapeworm
infections and is commercially available. Be sure to consult a veterinarian
before making any changes to your deworming program.
QUEST and QUEST PLUS are proven safe for use in all breeds of horses and
ponies. They are also approved for use in breeding mares and stallions, and
foals six months of age and older. For more information on QUEST and QUEST PLUS,
visit www.Questhorse.com.
Important
Safety Information Extreme
caution should be used when administering QUEST and QUEST PLUS to foals, young
and miniature horses, as over dosage may result in serious adverse reactions. Do
not use in sick, debilitated or underweight animals. These products should not
be used in other animal species, as severe adverse reactions, including
fatalities in dogs, may result. For more information on QUEST or QUEST PLUS
visit www.QUESThorse.com. About
Pfizer Animal Health Pfizer
Animal Health, a business unit of Pfizer Inc, is a world leader in the
discovery, development and manufacture of innovative animal health vaccines,
medicines, and diagnostic products. Pfizer Animal Health invests more in
research and development than any other animal health company. We work to assure
a safe, sustainable global food supply from healthy beef and dairy cattle,
swine, poultry and fish while helping dogs, cats and horses live healthier
longer lives. We strive to be the animal health company that provides full
healthcare solutions to veterinarians, livestock producers, and pet owners. To
learn more, visit www.us.animalhealth.pfizer.com. All
brands are the property of their respective owners. ©2011 Pfizer Inc. All
rights reserved -30-
References:
1 C.R. Reinemeyer, A.W. Farley, S.A. Kania, B.W. Rohrbach and R.H. Dressler, 48th
Annual Meeting of the American Association of Veterinary Parasitologists,
Denver, CO, July 2003. Updated West Coast Farm prevelance of tapeworm
infection data. Data on file. Pfizer Inc. 2009. 2 Steinbach, et al, Strongyle infection:
Consequences of Larvicidal Treatment of Horses with Fenbendazole
and Moxidectin. Vet Parasitology 139 (2006) 115-131. 3
Betancourt,A., ------------------------------------------------------ [i] Pfizer Animal Health in conjunction with The Gluck study
included three treatment groups of ponies infected naturally with small
strongyles and other parasites. The groups included a control, a group of ponies
given 5 daily doses of fenbendazole (20mg/kg/day) and a group given a single
dose of moxidectin (400 µg/kg) 3. By day 7, through day 28, all
ponies treated with moxidectin tested negative for parasite eggs, meaning a 100%
fecal egg reduction3. Ponies treated with moxidectin also showed no
significant proinflammatory cytokine gene expression prior to day 143.
The lack of significant proinflammatory cytokine gene expression was consistent
with the findings in the original 2006 study that revealed no severe
inflammatory intestinal lesions associated with encysted strongyle death in
moxidectin treated horses2. The ponies
treated with fenbendazole showed only an average 65% fecal egg reduction by day
72, and this sub-optimal efficacy was short-lived. By day 14,
strongyle fecal egg shedding was statistically identical to pre-treatment
levels. In other words, after the five dose PANACUR PowerPac was
administered, ponies were shedding eggs at a rate no different than before
treatment. Additionally concerning was the finding that fenbendazole
treated horses with encysted small strongyle infections experienced an
inflammatory response detectable in the peripheral circulation.
|
|
||||||||||||||||||||||||||||||||||||||||
|
Rocky
Mountain Rider Magazine • Montana Owned & Operated | ||||||||||||||||||||||||||||||||||||||||||
